Manish Chamoli

In a new Science study, researchers report that the limited number of remaining follicles of aged mice and women with premature ovarian insufficiency can be stimulated to grow and develop by modulating the stroma, the amorphous substance that surrounds them. This finding has potential implications for treating infertility. Learn more in a new #SciencePerspective: scim.ag/4a3GM72

Behind every scientific breakthrough is someone willing to take a bet on the future. Investors play a crucial role in turning discovery into impact — helping the field of longevity move from the lab bench to real-world solutions that extend healthspan and improve lives. This panel brings together leading voices who are doing exactly that: Lisa Lambie, Managing Partner at Maroon Venture Fund I LP, leads a U.S.-focused venture fund investing from Seed to Series A+ to close innovation and funding gaps in healthy aging, preventative healthcare, and precision medicine. Manish Chamoli, CSO Partner at LongGame Ventures, is a scientist-turned-investor applying 15+ years of research in aging biology to identify and fund bold, science-driven companies extending healthy human lifespan. Anthony Young, a biotech angel investor and serial entrepreneur, backs visionary founders developing transformative technologies with the potential to redefine human health. Join us as we explore how investors are fueling the next generation of longevity innovation and what it will take to get there. Full program here: a4li.org/a4li-longevity…. @ZuberLawler @Techweek_ #Longevity #Biotech #LATechWeek #InvestInHealthyAging #A4LI

Welcome @manish_chamoli, Partner at #LongGame #Ventures, as one of our #NEXTBIO2025 Judges ! 🎉 Together we're empowering the next wave of founders building a future powered by AI and Biology. #NEXTBIO2025

Tariffs, $150B+ in new pharma manufacturing, FDA’s PreCheck program, and NIH limits on foreign collaborations, all signs the U.S. wants to “build it here, keep it here.” Here’s a short piece on what that could mean for startups and biotech investors: manishchamoli.substack.com/p/build-it-her…

Cell therapies are breaking new ground, but too few patients can access them. What will it take to scale these treatments so more patients can benefit? Read the piece we wrote examining the bottlenecks and emerging solutions. longgamevc.substack.com/cp/171293688

We show a novel role for glycogen in neurons in protection against dementia. Glycogen accumulation is seen in fly, iPSC and human post mortem samples of Alzheimer’s disease. Breaking down glycogen rescues tauopathy by reducing ROS by enhancing PPP. nature.com/articles/s4225…

@kapahi_pankaj Congratulations

Silencing mitochondrial gene expression in living cells; science.org/doi/10.1126/sc…

🗓️ New Deadline: Apply by 15 June 2025 Join our dynamic research community and contribute to pioneering science and innovation. 🔬 Open Positions: • 03 Staff Scientist-III • 08 Staff Scientist-IV 📍 Key Research Areas: Immunology | Infectious Diseases | Precision Medicine | Therapeutics | Metabolic Disorders | Chronic Diseases | Aging | Cancer | Antimicrobial Resistance (AMR) | Genomics | AI/ML | and more 📑 Apply Online:nii.res.in/en/recruitment…

Preprint spotlight | Can damaged tRNAs drive aging? linkedin.com/posts/manishch…

𝐆𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 is a treatment that delivers fragments of DNA to cells to replace missing or defective DNA or to enhance cell function. Multiple approaches are under development, but currently approved gene therapies involve encapsulating a corrective or therapeutic gene within the shell of a modified virus that allows it to enter cells efficiently. The virally delivered corrective gene can integrate into the patient's own DNA (depicted here), which offers the potential for a lasting therapeutic effect, or it can remain extrachromosomal (separate from the patient's DNA), in which case, the dosage of the corrective gene (per cell) dilutes with cell division. To learn more about this NEJM Illustrated Glossary term, read the editorial “Genetic Medicine for Danon Disease” by Elizabeth M. McNally, MD, PhD (@emmcnally), and Melissa J. Spencer, PhD, from @NUFeinbergMed and @dgsomucla: nej.md/4irkBsB  Explore more terms: nej.md/glossary

@smartelegans @SABNAMRAHMAN3 @NImmunology Congratulations Dr. Sabnam Rahman!

Introducing Dr. Sabnam Sahin Rahman @SABNAMRAHMAN3 @NImmunology

Register now for "Molecular and Cellular Aging" Sept 10-11, La Jolla, CA. Immediately following NIH SenNet Mtg. Reg closes Aug 12. Submit Abstract for Short Talk/Poster. Registration limited. Please re-Tweet. rio.pitt.edu/2024-molecular…

@smartelegans @NImmunology @DBTIndia Thank you for sharing! I’m fortunate to have been your first Ph.D. student.

Proud moment for the lab!! An article featuring ⁦@manish_chamoli⁩, an alumni of our lab (first student!!!) at ⁦@NImmunology⁩. ⁦@DBTIndia.⁩ The Buck Institute & the Larry L. Hillblom Foundation: Making Dreams Possible buckinstitute.org/news/the-buck-…

@Systems_Immunol Thank you.

Grateful for the support from the Larry L Hillblom Foundation, which has been crucial for my research and career. Special thanks to Peter J. Donnici, Prof. Ana Maria Cuervo, and the Scientific Advisory Board for their invaluable support.

@smartelegans Thank you so much! I owe a lot of my success to your mentorship.

Congratulations Manish. Immensely proud of you!! Keep rising.

Join us on Mon, Aug 12 at Buck (or on Zoom) for the Inaugural Judith Campisi Symposium! Cellular Senescence: The Road to Immortality. Featured Speakers include @nes047, @Thomas_Rando, @JHElisseeff, and Miranda Orr @Orr_Lab Register today: buckinstitute.org/events/cellula…

Impressive study showing that inhibiting interleukin-11, a pro-inflammatory cytokine, extends lifespan in mice by 25%. Both genetic deletion and an anti-IL-11 drug worked, and it's exciting that anti-IL-11 therapies are already in human clinical trials. nature.com/articles/s4158…

Interested in ketone bodies and BHB? I had a lot of fun writing this one pager intro/catch-all with @BriannaStubbs for Cell Press, check it out here: authors.elsevier.com/a/1jRnS3jDgWq3…. Proud to call this my first, first-author pub!